For more than 15 years, virologist Chris Buck has worked to develop a vaccine against BK polyomavirus, a pathogen that quietly infects most people but can cause devastating illness in transplant recipients and others with weakened immune systems. Now Buck has taken that effort in an unexpected direction: he has consumed what may be the first vaccine delivered in a beer.
The Virus Few Notice — Until It’s Dangerous
BK polyomavirus infects up to 91 percent of children by age 9. In most people, it remains dormant for life. But in kidney transplant recipients, immunosuppressing drugs can allow the virus to reactivate, damaging the transplanted organ and sometimes leading to organ loss. A related virus, JC polyomavirus, can trigger a severe brain disease in transplant patients.
High antibody levels before transplant appear protective, which has driven a long search for a vaccine. Buck’s research group at the National Cancer Institute has focused on building that protection using virus-like particles—empty shells composed of the viral outer protein VP1. These particles mimic the structure of the virus but do not contain infectious genetic material.
In rhesus monkeys, injected virus-like particles produced antibody levels that remained elevated for approximately 2 years. The data suggested a conventional injectable vaccine could offer durable protection.
Yeast, Mice and an Unexpected Result
Buck’s team then explored alternative delivery routes in mice. They engineered baker’s yeast, Saccharomyces cerevisiae, to manufacture empty polyomavirus-like particles. Ground-up yeast administered through the nose triggered antibodies, though less effectively than injections. Scratching the preparation into the skin also worked. Feeding mice dead yeast failed, aligning with the common belief that oral vaccines require live organisms capable of infecting intestinal cells.
Then came a surprise. When mice were fed whole, live yeast mixed into their food, they produced antibodies. “We repeated this experiment a couple of times. I was reluctant to believe it,” Buck said. The results suggested that intact virus-like particles carried by live yeast could survive the stomach’s acidic environment and interact with immune cells in the gut.
If confirmed, the approach could expand oral vaccine strategies. Live yeast appeared capable of functioning as a delivery vehicle, potentially ferrying immune-stimulating proteins through digestion and into contact with the body’s defenses.
From Laboratory Concept to Pint Glass
Encouraged by the mouse data, Buck tested the approach on himself. Over five days, followed by two booster rounds weeks apart, he drank beer brewed with yeast engineered to produce polyomavirus-like particles. He monitored antibody levels using finger-prick blood tests.
Antibodies against certain BK subtypes rose to levels considered protective for transplant patients. His brother and other family members, all adults of legal drinking age, also consumed the beer without reported adverse effects, though detailed antibody measurements beyond Buck’s own are limited. The findings have not undergone peer review.
The idea hinges partly on regulatory distinctions. “If you can eat something, you can sell it as a dietary supplement product,” or food, Buck said. Dietary supplements are regulated differently from drugs and do not undergo the same multistage clinical trials designed to establish safety and efficacy.
Buck argues that the yeast and viral shell components meet the standard of being generally regarded as safe. At the same time, he acknowledges the product’s dual identity. “Vaccines are drugs. We all know this. But just because something is a drug does not mean it can’t also be a food,” he said.
Innovation, Oversight and Public Trust
The experiment has sparked debate within the scientific community. Michael Imperiale, a virologist at the University of Michigan Medical School, warned against drawing conclusions from such limited testing and stressed that vaccines for transplant patients must pass rigorous safety and efficacy trials.
Bryce Chackerian of the University of New Mexico recognizes the scientific intrigue but defends established safeguards. “I believe in our system of testing vaccines. I think it’s really important for making sure that we have safe products that go into people and that we don’t undermine the public trust in vaccines,” he said. Ethicist Arthur Caplan offered a sharper caution: “This is not the place for do-it-yourself.”
At the same time, some researchers view the yeast-based strategy as a legitimate scientific advance deserving further controlled study. The mouse experiments demonstrate that live yeast can serve as a biological carrier for virus-like particles. If future trials validate safety and effectiveness, the platform could extend beyond polyomaviruses to other infectious diseases.
For now, vaccine beer remains an experiment at the intersection of immunology and regulation. The science behind virus-like particles and yeast delivery is tangible and testable. The larger question is whether that science will move through the established clinical trial system or remain a provocative proof of concept.
If carefully evaluated through rigorous testing, yeast-based oral vaccines could eventually offer a simpler, scalable way to confer immunity, although beer as a delivery vehicle would be suitable only for adults. The path forward will depend not only on scientific replication but also on navigating the delicate balance between innovation, oversight and public trust.
Did you enjoy this blog post? Check out our other blog posts as well as related topics on our Webinar page.
QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and India. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, PBMC processing, central safety labs, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, turnkey laboratories, Phase I/II clinical units, and multi-site clinical research services. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance, and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.